. . "Acitretina"@en . . . . "55079-83-9"@en . . "An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. [PubChem]"@en . . "(all-e)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic acid"@en . "all-trans-3,7-Dimethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid"@en . . . "Acitretine"@en . . "Soriatane"@en . "The mechanism of action of acitretin is unknown, however it is believed to work by targeting specific receptors (retinoid receptors such as RXR and RAR) in the skin which help normalize the growth cycle of skin cells."@en . . . . . . "approved"@en . . "Oral absorption of acitretin is optimal when given with food, and is linear and proportional with increasing doses from 25 to 100 mg. Approximately 72% (range 47% to 109%) of the administered dose was absorbed after a single 50 mg dose of acitretin was given to 12 healthy subjects."@en . . . . . "Both parent compound and isomer are further metabolized into chain-shortened breakdown products and conjugates, which are excreted. The chain-shortened metabolites and conjugates of acitretin and cis-acitretin are ultimately excreted in the feces (34% to 54%) and urine (16% to 53%)."@en . "Yatendra Kumar, \"Process for the preparation of acitretin.\" U.S. Patent US20040192949, issued September 30, 2004."@en . . " "@en . . . "Acetretin"@en . . . . . . . . . . . . "Acitretin"@en . . "Oral, rat: LD₅₀ = >4000 mg/kg. Symptoms of overdose include headache and vertigo."@en . "49 hours (range 33 to 96 hours)"@en . . . . . . "Acitretinum"@en . "Neotigason"@en . . . . "Over 99.9% bound to plasma proteins, primarily albumin."@en . "For the treatment of severe psoriasis in adults."@en . . "Etretin"@en . . . . . . "Humans and other mammals"@en . . . . . "Acitretin"@en . . .